Pharma & Biotech

The acquisition of 2Seventy Bio by Bristol Myers Squibb in March 2025 for $286 million has effectively rendered the company's...

Medical technology company AngioDynamics is experiencing substantial momentum following the release of its quarterly financial results, which significantly surpassed market...

Assembly Biosciences delivered a stunning market surprise with exceptional clinical data for its investigational herpes treatment, ABI-5366. The biopharmaceutical company's...

The U.S. Food and Drug Administration has removed the clinical hold on Ocugen's promising ocular therapeutic candidate OCU200, clearing the...

The corporate transformation of Ikena Oncology into ImageneBio has reached a significant administrative milestone with the recent submission of regulatory...

After an extended period of decline, Abeona Therapeutics is demonstrating renewed momentum. The biotechnology firm is gaining traction from a...

Investors in Idorsia received an unexpected jolt as the biotechnology firm unveiled plans for a substantial capital increase through an...

The investment community is losing faith in Gerresheimer at an alarming rate. Following closely on the heels of a recent...

The biotechnology sector faces renewed scrutiny as Iovance Biotherapeutics experiences significant market pressure. Disappointing quarterly performance and emerging class action...

The healthcare sector is witnessing a notable divergence in performance, with Johnson & Johnson emerging as a standout performer. While...